Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PLD-107
- Development stage
- Unknown
- Lead developer
- Pelemed
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Oral
01
Overview
PLD-107 is an investigational antibody-drug conjugate (ADC) being developed by Pelemed for the treatment of oncology indications, including acute myeloid leukemia (AML) and various solid tumors. The therapeutic candidate is designed to deliver a novel cytotoxic payload directly to malignant cells. As of 2024, the program is in the discovery phase, and specific details regarding the target antigen and the chemical nature of the payload have not been publicly disclosed by the developer.
Beyond the preview
Go deeper on PLD-107.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PLD-107.